Form 4: Ironwood Pharmaceuticals Director Jay Shepard Trades Shares
Insider Transaction Report
Ironwood Pharmaceuticals Director Jay Shepard reported a transaction involving Class A Common Stock on June 16, 2026.
Summary
- Jay Shepard, a Director at Ironwood Pharmaceuticals Inc., reported a transaction on June 16, 2026.
- The transaction involved the acquisition of 63,481 shares of Class A Common Stock.
- These shares were acquired at a price of $0.
- Following this transaction, Shepard beneficially owns 235,036 shares of Class A Common Stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard disclosure of a director's stock grant and does not inherently signal positive or negative performance for the company.
Positives
- Director Jay Shepard acquired a significant number of Class A Common Stock shares (63,481) at no cost, indicating a potential long-term commitment or compensation structure.
- The acquisition of shares at $0 suggests a grant or award, which can be viewed positively as it aligns director interests with the company's performance without immediate personal financial outlay.
Negatives
- The filing does not detail the specific reasons for the acquisition, leaving room for speculation about the nature of the award (e.g., performance-based, retention, or standard compensation).
Future Outlook
The filing does not contain forward-looking statements or guidance.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into the holdings and activities of company directors and officers. This specific filing indicates a stock grant to a director, a common practice in executive compensation to align incentives with shareholder value.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compensation Policy Update | The restricted stock was granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy. | 01/01/2024 | Establishes the framework for director compensation, including vesting schedules for equity awards. |
Stakeholder Impact
- Shareholders: Increased transparency into director compensation and potential alignment of director interests with shareholder value.
- Employees: May indirectly signal the company's compensation strategy for key personnel.
- Management: Reinforces the compensation structure for non-employee directors.
Next Steps
- The restricted stock vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year.
Key Dates
| Date | Description |
|---|---|
| 01/01/2024 | Effective date of the Second Amended and Restated Non-employee Director Compensation Policy. |
| 06/16/2026 | Date of the earliest transaction reported. |
| 06/16/2026 | Transaction date for the acquisition of Class A Common Stock. |
| 06/17/2026 | Date of signature for the filing. |
Keywords
Ironwood Pharmaceuticals, IRWD, Form 4, Director Transaction, Class A Common Stock, Beneficial Ownership, Securities Exchange Act
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.